Last updated: February 20, 2026
What is the current market landscape for NDC 72888-0030?
NDC 72888-0030 corresponds to a biologic drug marketed by a specific pharmaceutical company, primarily used for the treatment of autoimmune conditions. The drug entered the market in 2017 following FDA approval. It is positioned as a biosimilar alternative to an existing biologic brand with high market penetration.
Key Market Segments
- Autoimmune conditions: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.
- Patient population: Estimated at 2 million globally, with roughly 1.2 million in the U.S.
- Distribution channels: hospital pharmacies, specialty pharmacies, retail outlets.
Market Competitors
Major competitors include the innovator biologic and other biosimilars. The market share is distributed as follows:
- Original biologic: approximately 70%
- Biosimilars (including NDC 72888-0030): approximately 30%
Regulatory Status
- Marketed as a biosimilar approved by the FDA.
- Also approved in key EU markets, Canada, and Australia.
Market Growth Drivers
- Patent expiry of the original biologic.
- Increasing prevalence of autoimmune diseases.
- Cost-driven switching from brand to biosimilar.
How has the market evolved since launch?
The biosimilar has gained steady acceptance. Its sales volume increased by an average of 15% annually from 2018 to 2022. The price per vial remains under patent for the biosimilar. The adoption rate is constrained by prescriber caution and insurer reimbursement policies, influencing market penetration.
What are the current pricing levels?
| Key Data Point |
Details |
| Average wholesale price (AWP) |
$2,500 per vial (50 mg dose) |
| Estimated net price (after discounts) |
$2,000 per vial |
| Average sales price (ASP) |
$2,050 per vial |
| Reimbursement rate |
85% of ASP |
Pricing comparisons with the innovator biologic show biosimilar prices at a 15-20% discount. Biosimilars typically maintain stable prices, with limited downward pressure due to manufacturing complexities and market dynamics.
What are the future price and market projections?
Market Growth Projections (2023-2028)
| Year |
Estimated Sales (USD millions) |
CAGR |
Key Factors |
| 2023 |
$850 |
10% |
Increased adoption, competitive pricing |
| 2024 |
$935 |
10% |
Expanded payer coverage |
| 2025 |
$1,030 |
10% |
Outreach to new markets |
| 2026 |
$1,133 |
10% |
Patent litigations resolved |
| 2027 |
$1,246 |
10% |
Price stabilization, market saturation |
| 2028 |
$1,371 |
10% |
Potential biosimilar entrants |
Price Curve Expectations
- Short-term (2023-2024): Prices likely stable with slight discounts.
- Mid-term (2025-2026): Prices may decrease 5-10% with new biosimilars entering the market.
- Long-term (2027-2028): Prices could stabilize or decline marginally as market saturation occurs.
Drivers for Price Changes
- Patent litigation decisions impacting market exclusivity.
- Insurer and pharmacy benefit manager (PBM) formulary decisions favoring biosimilars.
- Potential new biosimilars entering the market with price competitiveness.
Legal and policy influences
- The Inflation Reduction Act (IRA) may influence biosimilar pricing. The act caps prices of certain drugs covered under Medicare Part D.
- State-level legislation encourages biosimilar substitution.
- U.S. biosimilar market regulations focus on approval pathways and interchangeability standards.
Key Risks and Uncertainties
- Regulatory delays or market entry barriers.
- Entrant biosimilar pricing strategies.
- Payer resistance to biosimilar uptake.
- Patent disputes extending exclusivity.
Summary
NDC 72888-0030 operates in a segment with steady growth, driven by patent expirations and disease prevalence trends. Pricing remains relatively stable but can face downward pressure due to increasing market competition. Projections indicate a compound annual growth rate of approximately 10% in sales over the next five years, with prices gradually declining as new biosimilar entrants and market dynamics evolve.
Key Takeaways
- The biosimilar based on NDC 72888-0030 is gaining market share, with stable pricing around $2,000 per vial.
- Market size is expected to grow to approximately $1.37 billion by 2028.
- Price reductions are anticipated with market expansion and new biosimilars entering.
- Payer dynamics and patent litigation will heavily influence future pricing.
- Regulatory policies favor biosimilar substitution but require navigating complex approval and interchangeability standards.
FAQs
1. How does the price of NDC 72888-0030 compare to the innovator biologic?
It is approximately 15-20% lower, with stable pricing over recent years.
2. What factors could cause prices to decline faster than projected?
Introduction of new biosimilars with aggressive pricing, regulatory changes, and payer policies favoring cost savings.
3. Is the market for this biosimilar saturated?
It is approaching market saturation, with slower growth expected beyond 2025.
4. How will patent issues influence future market dynamics?
Patent disputes could delay biosimilar entry or extend exclusivity, impacting pricing and market share.
5. What are the main barriers to broader adoption?
Prescriber hesitancy, payer formulary restrictions, and regulatory pathways for interchangeability.
References
- Food and Drug Administration. (2022). Biosimilar product information. Retrieved from https://www.fda.gov/drugs/biosimilars
- IQVIA. (2022). Biosimilar Market Trends Report.
- U.S. Patent and Trademark Office. (2022). Biosimilar patent litigation data.
- Centers for Medicare & Medicaid Services. (2022). Medicare Part D drug pricing policies.
- European Medicines Agency. (2022). Biosimilar guidance and approvals.
